Kenvue, the parent company of Tylenol, refutes U.S. regulatory agencies' opposition to labeling regarding the use of medication during pregnancy and its association with autism risk

Kenvue (KVUE.US), the parent company of the pain reliever and fever reducer Tylenol, has made the most detailed defense of its flagship product, urging U.S. regulators to reject a citizen petition requesting that Tylenol be labeled with an autism association.

In documents submitted to the U.S. Food and Drug Administration (FDA) on the 17th of this month, Kenvue stated that the request to change the drug labeling lacks scientific basis and is also legally and procedurally inappropriate, with overwhelming evidence negating any claims of risk between the over-the-counter pain and fever medication and neurodevelopmental disorders